Wednesday 16 Jul, 2025 10:17 PM
Site map | Locate Us | Login
   Tech Mahindra Q1 PAT drops 2% QoQ to Rs 1,141 cr    PNC Infratech emerges as L-1 bidder for 1200 MW solar power project    Geojit Financial slumps as Q1 PAT tanks 38% YoY to Rs 28 cr    Lupin launches Loteprednol Etabonate Ophthalmic Suspension in the United States    Godrej Properties acquires 50-acre land in Raipur, Chhattisgarh    Platinum Industries CFO Gyandeep Mittal resigns    ITC Hotels spurts after Q1 PAT rises over 53% YoY in Q1 FY26    SBI gains as board OKs Rs 20,000 crore bond issue for FY26    Dixon Tech climbs on signing two strategic deals to boost electronics manufacturing    Gabriel India Ltd leads losers in 'A' group    DB Corp slides as Q1 PAT tanks 53% YoY to Rs 81 crore    Abans Financial Services Ltd leads losers in 'B' group    Volumes spurt at Network 18 Media & Investments Ltd counter    Onward Tech surges as Q1 profit jumps 20% QoQ    Saregama India Ltd drops for fifth straight session 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Dishman Carbogen slumps on dismal Q1 results
14-Aug-24   15:47 Hrs IST

On a consolidated basis, Dishman Carbogen Amcis reported net loss of Rs 77.57 crore in Q1 June 2024 as against net profit of Rs 17 crore in Q1 June 2023. Net sales declined 27.59% year-on-year to Rs 523.78 crore in Q1 June 2024. Net revenue was impacted mainly due to lower revenue in Switzerland and Netherlands.

Pre-tax loss stood at Rs 77.56 crore in Q1 June 2024 as against pre-tax profit of Rs 29.49 crore in Q1 June 2023.

EBITDA slumped 76.8% YoY to Rs 29.39 crore in Q1 June 2024. EBITDA margin stood at 5.6% in Q1 June 2024, lower than 17.5% in Q1 June 2023. This was primarily due to lower operating margins in its European subsidiaries, Carbogen Amcis AG and Carbogen Amcis BV. Factors contributing to this decline include delays in high-margin project realization, increased sales of lower-margin cholesterol products, and higher raw material costs. Additionally, the company incurred a larger operating loss in its French operations compared to the previous year.

During the quarter, cost of goods sold (COGS) fell 59.4% YoY to Rs 66.35 crore while employee expenses rose 7.3% YoY to Rs 316.82 crore.

Carbogen Amcis AG ' CRAMS revenue decreased by 39.6% YoY in Q1 FY25 primarily due to shifting of a major development project and deferment of shipment of a commercial batch to the next quarters. This had an impact of CHF 9.8 m in revenue and CHF 3.92 m in operating profit due to timing difference.

Carbogen Amcis BV' Cholesterol and Vitamin D analogues revenue decreased by 16.4% YoY in Q1 FY25 primarily due to lower sales of Vitamin D analogs by 38%. This is expected to pick up in revenue in the remainder part of the year.

DCAL India ' NCE APIs and Intermediates revenue increased by 114.5% YoY in Q1 FY25 primarily due to increase in commercial supplies from Bavla site after the EDQM clearance.

DCAL India ' Quats & Generics revenue decreased by 20.4% YoY in Q1 FY25 primarily due to slow down in agrochemical sector, which is expected to pick up in the second half of the year.

Dishman Carbogen Amcis is a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical companies. The company has global presence with development and manufacturing sites in Switzerland, UK, France, Netherlands, India and China.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 42716622
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL Securities Private Limited